Table 1 Base–case scenario results.

From: Cost effectiveness of pharmacogenetic-guided clozapine administration based on risk of HLA variants in Japan and the UK

 

General treatment schedule without HLA test

HLA-guided treatment schedule

Cost per patient/10 years (JPN/UK)

£16,487/£4211

£16,552/£4281

Incremental Cost (JPN/UK)

 

£65/£70

Effect per patient/10 years (QALYs: JPN/UK)

6.22608/5.82665

6.22917/5.82990

Incremental effect (QALYs: JPN/UK)

 

0.00309/0.00326

ICER (JPN/UK)

 

£21,024/£21,343

  1. JPN Japan, UK United Kingdom, QALY quality-adjusted life years, ICER incremental cost-effectiveness ratio.
Back to article page